The cluster of psychedelic drug companies — COMPASS Pathways, AtaiBeckley, Mind Medicine, others — has already surged on the executive order and will likely be trading even higher by October as FDA decision timelines approach.
CMPS already +25% on EO day. Jefferies Buy initiated May 3. FDA Priority Voucher timeline creates structured sector catalysts. Multiple trial readouts expected. 83% reflects strong base case with inherent biotech volatility.